Botulinum toxin type A for refractory neurogenic detrusor overactivity in spinal cord injured patients in Singapore

Annals of the Academy of Medicine Singapore

Volumn 36, Issue 1, 2007, Pages 11-17

  Tow, Adela M ^a   Toh, Khai Lee ^a   Chan, Siew Pang ^a   Consigliere, David ^b  

^a TAN TOCK SENG HOSPITAL   (Singapore)

^b NATIONAL UNIVERSITY HOSPITAL   (Singapore)

Author keywords

Anticholinergics; Spinal cord injury; Urodynamics; Voiding

Indexed keywords

ANTIBIOTIC AGENT; BOTULINUM TOXIN A; CHOLINERGIC RECEPTOR STIMULATING AGENT; OXYBUTYNIN; TOLTERODINE;

ADULT; AGED; ARTICLE; AUTONOMIC DYSREFLEXIA; CLINICAL ARTICLE; CONSTIPATION; CONTROLLED STUDY; DETRUSOR MUSCLE; DRUG EFFICACY; FEMALE; HUMAN; MALE; NEUROGENIC BLADDER; SPINAL CORD INJURY; URINARY TRACT INFECTION; URINARY URGENCY; XEROSTOMIA;

EID: 34047150452     PISSN: 03044602     EISSN: 29724066     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. Wyndaele JJ, Madersbacher H, Kovindha A. Conservative treatment of the neuropathic bladder in spinal cord injured patients. Spinal Cord 2001;39:294-300.
2. Chua HC, Tow A, Tan ES. The neurogenic bladder in spinal cord injury - pattern and management. Ann Acad Med Singapore 1996;25:553-7.
3. Szollar SM, Lee SM. Intravesical oxybutynin for spinal cord injury patients. Spinal Cord 1996;34:284-7.
4. Malone-Lee J, Shaffu B, Anand C, Powell C. Tolterodine: superior tolerability than and comparable efficacy to oxybutynin in individuals 50 years old or older with overactive bladder: a randomized controlled trial. J Urol 2001;165:1452-6.
5. Haab F, Cardozo L, Chapple C, Riddler AM; Solifenacin Study Group. Long-term open-label solifenacin treatment associated with persistence with therapy in patients with overactive bladder syndrome. Eur Urol 2005;47:376-84.
6. Giannantoni A, Di Stasi SM, Stephen RL, Bini V, Constantini E, Porena M. Intravesical resiniferatoxin versus botulinum-A toxin injections for neurogenic detrusor overactivity: a prospective randomized study. J Urol 2004;172:240-3.
7. Vignes JR, De Seze M, Dobremez E, Joseph PA, Guerin J. Sacral neuromodulation in lower urinary tract dysfunction. Adv Tech Stand Neurosurg 2005:30:177-24.
8. Kutzenberger J, Domurath B, Sauerwein D. Spastic bladder and spinal cord injury: seventeen years of experience with sacral deafferentation and implantation of an anterior root stimulator. Artif Organs 2005;29:239-41.
9. Edlund C, Peeker R, Fall M. Clam ileocystoplasty: successful treatment of severe bladder overactivity. Scand J Urol Nephrol 2001;35:190-5.
10. Stohrer M, Schurch B, Kramer G, Schmid D, Gaul D, Hauri D. Botulinum A toxin in the treatment of detrusor hyperreflexia in spinal cord injury. A new alternative to medical and surgical procedures? Neurourol Urodyn 1999;18:401-2.
11. Schurch B, Schmid DM, Stohrer M. Treatment of neurogenic incontinence with botulinum toxin A. N Engl J Med 2000;342:665.
12. Schurch B, Stohrer M, Kramer G, Schmid DM, Gaul G, Hauri D. Botulinum toxin A for treating detrusor hyperreflexia in spinal cord injured patients: a new alternative to anticholinergic drugs? Preliminary results. J Urol 2000;164:692-7.
13. Schurch B, de Seze M, Denys P, Chartier-Kastler E, Haab F, Everaert K, et al. Botulinum toxin type A is a safe and effective treatment for neurogenic urinary incontinence: results of a singe treatment, randomized placebo controlled 6-month study. J Urol 2005;174:196-200.
14. Reitz A, Stohrer M, Kramer G, Popolo GD, Chartier-Kastler E, Pannek J, et al. European experience of 200 cases treated with botulinum-A toxin injections into the detrusor muscle for urinary incontinence due to neurogenic detrusor overacitivty. Eur Urol 2004;45:501-5.
15. Schulte-Baukloh H, Weiss C, Schobert J, Stolze T, Sturzebecher B, Knispel HH. Subjective patient satisfaction after injection of botulinum toxin in detrusor overactivity [Germany]. Aktuelle Urol 2005;36:230-3.
16. Haferkamp, A, Schurch B, Reitz A, Krengel U, Grosse J, Kramer G, et al. Lack of ultrastructural detrusor changes following endoscopic injection of botulinum toxin type A in overactive neurogenic bladder. Eur Urol 2004;46:784-91.
17. Kapfhammer JP. Myelin-associated neurite growth inhibitors: regulators of plastic changes of neural connections in the central nervous system. Prog Brain Res 1996;108:183-202.
18. Apostolidis A, Popat R, Yiangou Y, Cockayne D, Ford AP, Davis JB, et al. Decreased sensory receptors P2X3 and TRPV1 in suburothelial nerve fibers following intradetrusor injections of botulinum toxin for human detrusor overactivity. J Urol 2005 Sep;174:977-82; discussion 982-3.
19. Grosse J, Kramer G, Stoher M. Success of repeated detrusor injections of botulinum toxin in patients wit severe neurogenic detrusor overactivity and incontinence. Eur Urol 2005;47:653-9.
20. Schulte-Baukloh H, Knispel HH, StolzeT, Weiss C, Michael T, Miler K. Repeated botulinum-A toxin injections in treatment of children with neurogenic detrusor overactivity. Urology 2005;66:865-70.
21. Chancellor MB, Rivas DA, Erhard MJ, Hirsch IH, Bagley DH. Flexible cystoscopy during urodynamic evaluation of spinal cord injured patients. J Endourol 1993;7:531-5.
22. Wyndaele JJ, Van Dromme SA. Muscular weakness as a side effect of botulinum toxin injection for neurogenic detrusor overactivity. Spinal Cord 2002;40:599-600.
23. De Leaf K, Wyndaele JJ. Adverse events after botulinum A toxin injection for neurogenic voiding disorders. Spinal Cord 2005;43:397-9.
24. Kuo HC. Therapeutic effects of suburothelial injection of botulinum A toxin for neurogenic detrusor overactivity due to chronic cerebrovascular accident and spinal cord lesions. Urology 2006;67:232-6.
25. Patki PS, Hamid R, Arumugam K, Shah PJR, Graggs M. Botulinum toxin-type A in the treatment of drug resistant neurogenic detrusor overactivity secondary to traumatic spinal cord injury. BJU Int 2006;98:77-82.
26. Ruffion A, Capelle O, Parapel P, Leriche B, Leriche A, Grise P. What is the optimum dose of type A botulinum toxin for treating neurogenic bladder overactivity? BJU Int 2006;97:1030-4.
27. Leippold T, Reitz A, Schurch B. Botulinum toxin as a new therapy option for voiding disorders: current state of the art. Eur Urol 2003;44:165-74.